Evidence map›Paper›PMID 32319040›Full record

ArticleAdvances in therapy2020

Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.

Kaiyan Liu, Depei Wu, Junmin Li, Hu Chen, Hongmei Ning, Ting Zhao, Haiping Dai, Li Chen, Eric Mangin, Gregory A Winchell and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02387983 (Pharmacokinetics and Safety of Solid Oral Posaconazole), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02387983 phase1completednot on this map

Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2015 to 2016Enrolled65ConditionsFungal InfectionArmsPosaconazole
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Kaiyan LiuPeking University People's Hospital, Beijing, China. liukaiyan@medmail.com.cn.
Depei WuThe First Affiliated Hospital of Soochow University, Suzhou, China.
Junmin LiShanghai Ruijin Hospital, Beijing, China.
Hu ChenThe 307th Hospital of Chinese People's Liberation Army, Beijing, China.
Hongmei NingThe 307th Hospital of Chinese People's Liberation Army, Beijing, China.
Ting ZhaoPeking University People's Hospital, Beijing, China.
Haiping DaiThe First Affiliated Hospital of Soochow University, Suzhou, China.
Li ChenShanghai Ruijin Hospital, Beijing, China.
Eric ManginMerck & Co., Inc., Kenilworth, NJ, USA.
Gregory A WinchellCertara USA, Inc., Princeton, NJ, USA.
Hetty WaskinMerck & Co., Inc., Kenilworth, NJ, USA.
Jun JiangMerck & Co., Inc., Kenilworth, NJ, USA.
Yanping QiuMerck & Co., Inc., Kenilworth, NJ, USA.
Xu Min ZhaoMerck & Co., Inc., Kenilworth, NJ, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US307th Hospital of Chinese People’s Liberation Army · CNRuijin Hospital · CNCertara (United States) · USFirst Affiliated Hospital of Soochow University · CNPeking University · CNPeking University People's Hospital · CNSoochow University · CN

Funding

Merck Sharp & Dohme No award number
6 · The paper itself

Abstract

introductionThis study characterized the multidose pharmacokinetic (PK) characteristics of posaconazole tablets used as prophylactic antifungal therapy in Chinese patients with acute myelogenous leukemia (AML) at risk for invasive fungal infection (IFI).

methodsParticipants in this open-label, single-arm, phase 1b study received posaconazole 300 mg twice daily on day 1 and then once daily for up to 28 days. In the intensive PK sampling subgroup, posaconazole was administered under fasting conditions on days 1 and 8, and blood samples were regularly collected over 24 h. Trough PK sampling was conducted in all participants on days 1, 2, 3, 8, 14, 21, and 28 without regard for food intake. Population PK characteristics were predicted using PK modeling. Primary endpoints were steady-state average concentration (C

resultsSixty-five adult Chinese participants were enrolled. On day 8, steady-state arithmetic mean C

conclusionIn Chinese AML patients, the posaconazole 300-mg tablet provided PK data comparable with those of previous studies and was generally well tolerated and efficacious. CLINICAL

trial registrationClinicalTrials.gov, NCT02387983.

Indexed as

Administration, OralAdolescentAdultAgedAntifungal AgentsChinaFastingFemaleHumansInvasive Fungal InfectionsMaleMetabolic Clearance RateMiddle AgedTabletsTriazolesYoung AdultAntifungal AgentsposaconazoleTabletsTriazolesPharmacokineticsPosaconazoleTriazole antifungal

Identifiers

PMID32319040
OpenAlexW3017007448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.